Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PI4KA | P42356 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 5/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906671 | 0.84 | GRM5 (0.41) | GRM5GRM1 | |
| SCHEMBL4132855 | 0.83 | GRM5 (0.36) | GRM5GRM1 | |
| SCHEMBL1637883 | 0.74 | GRM5 (0.57) | GRM5GRM1 | |
| SCHEMBL1637329 | 0.71 | HDAC8 (0.39) | TSHRSLC5A2 | |
| SCHEMBL188317 | 0.71 | KDM4E (0.43) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL906668 | 0.67 | GRM5 (0.46) | GRM5GRM1 | |
| SCHEMBL24930547 | 0.66 | CYP1A2 (0.41) | SLC5A2 | |
| SCHEMBL23511149 | 0.66 | PIK3CG (0.35) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL23498018 | 0.66 | HDAC6 (0.36) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG | |
| SCHEMBL904601 | 0.66 | SLC5A2 (0.41) | PIK3CDPIK3CAPIK3CBPI4KAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009123855-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | ELI LILLY AND COMPANY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253750-A1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | CYP3A4, IPO4, JAK3 | PIK3CD 488/4885PIK3CA 498/4885PIK3CB 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.